These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 28442261)
21. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Matsukawa J; Hori Y; Nishida H; Kajino M; Inatomi N Biochem Pharmacol; 2011 May; 81(9):1145-51. PubMed ID: 21371447 [TBL] [Abstract][Full Text] [Related]
22. [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate]. Matsukawa J; Inatomi N; Nishida H; Tsukimi Y Nihon Yakurigaku Zasshi; 2018; 152(3):104-110. PubMed ID: 30185727 [TBL] [Abstract][Full Text] [Related]
23. Discovery of novel benzimidazole derivatives as potent potassium-competitive acid blockers for the treatment of acid-related diseases. Wang M; Zhang C; Zhang Z; Xu X; He Y; Hu Y; Wang Y; Liu Y; Xia M; Cheng M Bioorg Chem; 2023 Aug; 137():106588. PubMed ID: 37167705 [TBL] [Abstract][Full Text] [Related]
24. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion. Kodama K; Fujisaki H; Kubota A; Kato H; Hirota K; Kuramochi H; Murota M; Tabata Y; Ueda M; Harada H; Kawahara T; Shinoda M; Watanabe N; Iida D; Terauchi H; Yasui S; Miyazawa S; Nagakawa J J Pharmacol Exp Ther; 2010 Aug; 334(2):395-401. PubMed ID: 20484556 [TBL] [Abstract][Full Text] [Related]
25. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456 [TBL] [Abstract][Full Text] [Related]
26. Crystal structures of the gastric proton pump. Abe K; Irie K; Nakanishi H; Suzuki H; Fujiyoshi Y Nature; 2018 Apr; 556(7700):214-218. PubMed ID: 29618813 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of gastric H Fujii T; Sugimoto K; Noda T; Shimizu T; Matsuya Y; Sakai H Biochem Biophys Res Commun; 2021 Aug; 567():177-182. PubMed ID: 34166915 [TBL] [Abstract][Full Text] [Related]
28. Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles. Kromer W; Postius S; Riedel R Pharmacology; 2000 May; 60(4):179-87. PubMed ID: 10828742 [TBL] [Abstract][Full Text] [Related]
29. Proton-Potassium (H(+)/K(+)) ATPases: Properties and Roles in Health and Diseases. Sakai H; Fujii T; Takeguchi N Met Ions Life Sci; 2016; 16():459-83. PubMed ID: 26860309 [TBL] [Abstract][Full Text] [Related]
30. Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs). Arikawa Y; Hasuoka A; Nishida H; Hirase K; Inatomi N; Takagi T; Tarui N; Kawamoto M; Imanishi A; Itoh F; Kajino M Bioorg Med Chem Lett; 2015; 25(10):2037-40. PubMed ID: 25891103 [TBL] [Abstract][Full Text] [Related]
31. Computational insights into the interaction mechanism of triazolyl substituted tetrahydrobenzofuran derivatives with H(+),K(+)-ATPase at different pH. Luo HJ; Wang JZ; Huang NY; Deng WQ; Zou K J Comput Aided Mol Des; 2016 Jan; 30(1):27-37. PubMed ID: 26667240 [TBL] [Abstract][Full Text] [Related]
32. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Sachs G; Shin JM; Briving C; Wallmark B; Hersey S Annu Rev Pharmacol Toxicol; 1995; 35():277-305. PubMed ID: 7598495 [TBL] [Abstract][Full Text] [Related]
33. Role of potassium in acid secretion. Geibel JP World J Gastroenterol; 2005 Sep; 11(34):5259-65. PubMed ID: 16149129 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. Laine L; Sharma P; Mulford DJ; Hunt B; Leifke E; Smith N; Howden CW Am J Gastroenterol; 2022 Jul; 117(7):1158-1161. PubMed ID: 35294415 [TBL] [Abstract][Full Text] [Related]
35. Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase. Tabuchi Y; Yashiro H; Hoshina S; Asano S; Takeguchi N Br J Pharmacol; 2001 Dec; 134(8):1655-62. PubMed ID: 11739241 [TBL] [Abstract][Full Text] [Related]
36. The physiological background behind and course of development of the first proton pump inhibitor. Lundell L Scand J Gastroenterol; 2015 Jun; 50(6):680-4. PubMed ID: 25857639 [TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Kong WM; Sun BB; Wang ZJ; Zheng XK; Zhao KJ; Chen Y; Zhang JX; Liu PH; Zhu L; Xu RJ; Li P; Liu L; Liu XD Acta Pharmacol Sin; 2020 Jun; 41(6):852-865. PubMed ID: 31969689 [TBL] [Abstract][Full Text] [Related]
38. Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases. Srinivas NR Aliment Pharmacol Ther; 2016 Feb; 43(3):442-3. PubMed ID: 26782116 [No Abstract] [Full Text] [Related]
39. The H+/K+-ATPase inhibitory activities of Trametenolic acid B from Trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells. Zhang Q; Huang N; Wang J; Luo H; He H; Ding M; Deng WQ; Zou K Fitoterapia; 2013 Sep; 89():210-7. PubMed ID: 23742858 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of gastric H+,K+-ATPase by 4-(2-butyl-6,7-dichloro-2-cyclopentylindan-1-on-5-yl)oxybutyric acid (DCPIB), an inhibitor of volume-regulated anion channel. Fujii T; Takahashi Y; Takeshima H; Saitoh C; Shimizu T; Takeguchi N; Sakai H Eur J Pharmacol; 2015 Oct; 765():34-41. PubMed ID: 26277321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]